6 results match your criteria: "National Centre for Pediatric Gastroenterology[Affiliation]"
Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort-A Retrospective Study.
Inflamm Bowel Dis
February 2025
National Centre for Pediatric Gastroenterology, Children's Health Ireland at Crumlin, Dublin, Ireland.
Background: Proactive drug monitoring in our national cohort of children with inflammatory bowel disease suggested that 5 mg/kg dosing of infliximab (IFX) was associated with inadequate trough levels (TLs), thus we commenced empiric 10 mg/kg dosing in 2019.
Methods: This was a retrospective study of patients commenced on 5 or 10 mg/kg IFX between 2018 and 2020. The primary outcome was pre-fourth TL ≥5 µg/mL.
Human ITGAV variants are associated with immune dysregulation, brain abnormalities, and colitis.
J Exp Med
December 2024
Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, Canada.
Article Synopsis
- Integrin alpha V is crucial for cell adhesion and signaling during development, and mutations in its gene (ITGAV) can lead to serious health issues.
- In three families, biallelic variants were found that caused either dysfunctional protein production or the integrin being misplaced, resulting in severe developmental problems like eye and brain abnormalities, inflammatory bowel disease, and immune issues.
- Studies in patient cells and zebrafish models confirmed these mutations resulted in impaired immune signaling and developmental defects, linking the ITGAV variants to a newly identified human disease.
Early Life Exposure to Parental Crohn's Disease Is Associated With Offspring's Gut Microbiome, Gut Permeability, and Increased Risk of Future Crohn's Disease.
Gastroenterology
February 2025
Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada.
Body Surface Area-Based Dosing of Infliximab is Superior to Standard Weight-Based Dosing in Children With Very Early Onset Inflammatory Bowel Disease.
Gastro Hep Adv
November 2023
Division of Gastroenterology, Hepatology and Nutrition, SickKids Inflammatory Bowel Disease Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Background And Aims: Children with very early onset inflammatory bowel disease (VEO-IBD) are uniquely at risk of inadequate infliximab (IFX) exposure. We studied the association between standard body weight (BW)-based and body surface area (BSA)-based dosing strategies and outcomes.
Methods: We identified VEO-IBD patients treated with IFX before 9 years at a single center.
Outcomes of Tofacitinib Use in an Irish Pediatric Cohort.
JPGN Rep
August 2023
From the National Centre for Pediatric Gastroenterology, Children's Health Ireland, Dublin, Ireland.
Article Synopsis
- Pediatric ulcerative colitis (UC) is generally diagnosed more severely in children than in adults, and tofacitinib, a medication used since 2018, has limited data on its effectiveness for this age group.
- A retrospective study examined the outcomes of tofacitinib treatment at a national center in Ireland, analyzing clinical characteristics and response over time in pediatric patients with UC.
- Of 15 children studied, 8 achieved clinical remission after starting tofacitinib, showing a significant decrease in Pediatric Ulcerative Colitis Activity Index (PUCAI) scores from baseline, with no notable differences in outcomes between those receiving it alone versus those on a combination of therapies.
Mucosal Atrophy Predicts Poorer Outcomes in Pediatric Ulcerative Colitis-A National Inception Cohort Study.
J Pediatr Gastroenterol Nutr
May 2023
From National Centre for Pediatric Gastroenterology, CHI-Crumlin, Dublin, Ireland.
Background: Outcomes in pediatric ulcerative colitis (UC) are heterogeneous and predictors of disease course eagerly sought. Mucosal atrophy (MA) is characterized by histological abnormalities of colonic intestinal glands.
Objective: To determine the prevalence of MA in a national inception cohort of pediatric UC and its impact on outcomes.